Carl Koplin, MD | |
69 Pleasant Valley Rd # 3a, Barkhamsted, CT 06063-4008 | |
(860) 238-7252 | |
Not Available |
Full Name | Carl Koplin |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 69 Pleasant Valley Rd # 3a, Barkhamsted, Connecticut |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1700853843 | NPI | - | NPPES |
080129757 | Other | CT | MEDICARE RAIL ROAD |
279747 | Other | CT | NATIONAL BOARD OF MEDICAL EXAMINERS |
001272467 | Medicaid | CT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 027246 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Carl Koplin, MD Po Box 167, Barkhamsted, CT 06063-0167 Ph: (860) 238-7252 | Carl Koplin, MD 69 Pleasant Valley Rd # 3a, Barkhamsted, CT 06063-4008 Ph: (860) 238-7252 |
News Archive
Schizophrenia patients with a relatively high quality of life show hypoperfusion in the superior temporal sulcus compared with those with a relatively low quality of life.
Intradigm Corporation announced today its collaboration with Chinese academic and biotech groups has achieved clear evidence of prophylactic and therapeutic effects of siRNA (small interfering RNA) agents in Rhesus monkey to treat SARS coronavirus (SCV) respiratory infection.
A major breakthrough in the development of stem cell-derived brain cells has put researchers on a firm path towards the first ever stem cell transplantations in people with Parkinson's disease. A new study presents the next generation of transplantable dopamine neurons produced from stem cells. These cells carry the same properties as the dopamine neurons found in the human brain.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).
› Verified 5 days ago